Evripidis Kaltsonoudis1, Eleftherios Pelechas1, Paraskevi V Voulgari1, Alexandros A Drosos2. 1. Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Stavrou Niarchou Blv 45500, Ioannina, Greece. 2. Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Stavrou Niarchou Blv 45500, Ioannina, Greece. Electronic address: adrosos@cc.uoi.gr.
Abstract
OBJECTIVES: To estimate the size of unmet needs in the treatment of early Rheumatoid Arthritis (eRA), using all the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or biological DMARDs (bDMARDs) in a long-term observational study. MATERIALS AND METHODS: 538 patients with eRA were evaluated. The 2010 ACR/EULAR classification criteria were used. All patients were csDMARDs and bDMARDs-naive with disease duration less than one year. They were treated according to EULAR and ACR recommendations for RA. All the csDMARDs and bDMARDs were used. Clinical, laboratory findings with the disease activity score-28 and treatment decisions were all recorded as well as adverse drug reactions, reason of therapy termination, disease complications and comorbidities. RESULTS: Methotrexate (58%) and Infliximab (37%) where the first csDMARD and bDMARD choice respectively. During follow-up, 14 patients were lost and 7 developed comorbidities. The final results are referred to 517 patients. Among those, 66% were treated with csDMARDs as monotherapy or in combination therapy with sustained low disease activity (LDA). However, 3.2% from this group neither achieved LDA, nor received bDMARDs, due to comorbidities. On the other hand, 34% were treated with bDMARDs with or without csDMARDs. The majority of them demonstrated sustained LDA. From this group, 17.7% never achieved LDA, despite that they switched and received all bDMARDs. Thus, 20.9% of our patients never achieved LDA. CONCLUSIONS: Using the current recommendations for RA therapy we successfully treated the majority of our patients. However, we found that the size of gap and the unmet needs for treatment is about 20%.
OBJECTIVES: To estimate the size of unmet needs in the treatment of early Rheumatoid Arthritis (eRA), using all the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or biological DMARDs (bDMARDs) in a long-term observational study. MATERIALS AND METHODS: 538 patients with eRA were evaluated. The 2010 ACR/EULAR classification criteria were used. All patients were csDMARDs and bDMARDs-naive with disease duration less than one year. They were treated according to EULAR and ACR recommendations for RA. All the csDMARDs and bDMARDs were used. Clinical, laboratory findings with the disease activity score-28 and treatment decisions were all recorded as well as adverse drug reactions, reason of therapy termination, disease complications and comorbidities. RESULTS:Methotrexate (58%) and Infliximab (37%) where the first csDMARD and bDMARD choice respectively. During follow-up, 14 patients were lost and 7 developed comorbidities. The final results are referred to 517 patients. Among those, 66% were treated with csDMARDs as monotherapy or in combination therapy with sustained low disease activity (LDA). However, 3.2% from this group neither achieved LDA, nor received bDMARDs, due to comorbidities. On the other hand, 34% were treated with bDMARDs with or without csDMARDs. The majority of them demonstrated sustained LDA. From this group, 17.7% never achieved LDA, despite that they switched and received all bDMARDs. Thus, 20.9% of our patients never achieved LDA. CONCLUSIONS: Using the current recommendations for RA therapy we successfully treated the majority of our patients. However, we found that the size of gap and the unmet needs for treatment is about 20%.
Authors: Eleftherios Pelechas; Alexandra Papoudou-Bai; Paraskevi V Voulgari; Alexandros A Drosos Journal: Rheumatol Int Date: 2018-12-07 Impact factor: 2.631
Authors: Iris Navarro-Millán; Mangala Rajan; Geyanne E Lui; Lisa M Kern; Laura C Pinheiro; Monika M Safford; Sebastian E Sattui; Jeffrey R Curtis Journal: Semin Arthritis Rheum Date: 2020-07-23 Impact factor: 5.532
Authors: Nida Meednu; Javier Rangel-Moreno; Fan Zhang; Katherine Escalera-Rivera; Elisa Corsiero; Edoardo Prediletto; Edward DiCarlo; Susan Goodman; Laura T Donlin; Soumya Raychauduri; Michele Bombardieri; Costantino Pitzalis; Dana E Orange; Andrew McDavid; Jennifer H Anolik Journal: Cell Rep Date: 2022-05-03 Impact factor: 9.995
Authors: F Navarro; J M Martinez-Sesmero; A Balsa; C Peral; M Montoro; M Valderrama; S Gómez; F de Andrés-Nogales; M A Casado; Itziar Oyagüez Journal: Clin Rheumatol Date: 2020-04-17 Impact factor: 2.980
Authors: Ruediger B Mueller; Caroline Hasler; Florian Popp; Frederik Mattow; Mirsada Durmisi; Alexander Souza; Paul Hasler; Andrea Rubbert-Roth; Hendrik Schulze-Koops; Johannes von Kempis Journal: J Clin Med Date: 2019-09-26 Impact factor: 4.241